Symbols / TXG $20.46 -2.15%
TXG Chart
About
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Health Information Servi | Market Cap | 2.61B |
| Enterprise Value | 2.17B | Income | -43.54M | Sales | 642.82M |
| Book/sh | 6.24 | Cash/sh | 4.10 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1178 | IPO | — |
| P/E | — | Forward P/E | 125.27 | PEG | — |
| P/S | 4.07 | P/B | 3.28 | P/C | — |
| EV/EBITDA | -33.94 | EV/Sales | 3.38 | Quick Ratio | 3.95 |
| Current Ratio | 4.46 | Debt/Eq | 10.59 | LT Debt/Eq | — |
| EPS (ttm) | -0.35 | EPS next Y | 0.16 | EPS Growth | — |
| Revenue Growth | 0.60% | Earnings | 2026-05-07 | ROA | -6.40% |
| ROE | -5.78% | ROIC | — | Gross Margin | 69.13% |
| Oper. Margin | -9.42% | Profit Margin | -6.77% | Shs Outstand | 117.67M |
| Shs Float | 115.30M | Short Float | 22.90% | Short Ratio | 6.81 |
| Short Interest | — | 52W High | 23.56 | 52W Low | 6.78 |
| Beta | 2.21 | Avg Volume | 2.52M | Volume | 1.71M |
| Target Price | $20.14 | Recom | Buy | Prev Close | $20.91 |
| Price | $20.46 | Change | -2.15% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$20.14
Mean price target
2. Current target
$20.46
Latest analyst target
3. DCF / Fair value
$22.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$20.46
Low
$17.00
High
$25.00
Mean
$20.14
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-02 | main | Stifel | Buy → Buy | $25 |
| 2026-02-20 | main | UBS | Neutral → Neutral | $20 |
| 2026-02-13 | main | Stifel | Buy → Buy | $20 |
| 2026-02-13 | main | TD Cowen | Hold → Hold | $19 |
| 2026-01-27 | main | Leerink Partners | Market Perform → Market Perform | $20 |
| 2026-01-16 | main | Leerink Partners | Market Perform → Market Perform | $22 |
| 2026-01-07 | main | Leerink Partners | Market Perform → Market Perform | $20 |
| 2026-01-07 | main | TD Cowen | Hold → Hold | $18 |
| 2025-12-22 | main | Canaccord Genuity | Buy → Buy | $20 |
| 2025-12-15 | main | Barclays | Overweight → Overweight | $22 |
| 2025-12-11 | down | Citigroup | Buy → Neutral | $18 |
| 2025-12-02 | down | Morgan Stanley | Overweight → Equal-Weight | $20 |
| 2025-11-11 | main | Piper Sandler | Neutral → Neutral | $19 |
| 2025-11-07 | main | Canaccord Genuity | Buy → Buy | $19 |
| 2025-11-07 | main | JP Morgan | Neutral → Neutral | $15 |
| 2025-11-07 | main | UBS | Neutral → Neutral | $14 |
| 2025-11-07 | main | Barclays | Overweight → Overweight | $17 |
| 2025-09-11 | init | Piper Sandler | — → Neutral | $15 |
| 2025-08-12 | main | Morgan Stanley | Overweight → Overweight | $17 |
| 2025-08-08 | main | UBS | Neutral → Neutral | $13 |
News
RSS: Latest TXG news- Why Is 10x Genomics (TXG) Stock Soaring Today - Yahoo Finance Fri, 13 Feb 2026 08
- Torex Gold Resources (TSE:TXG) Share Price Passes Above 200 Day Moving Average - Here's Why - MarketBeat Wed, 11 Mar 2026 06
- (TXG) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily ue, 10 Mar 2026 22
- TXG Stock Surges 22% With A 6-day Spree On CEO Equity Grant - Trefis ue, 03 Mar 2026 20
- Cancer tools maker 10x Genomics slashes loss, aims for $625M sales in 2026 - Stock Titan hu, 12 Feb 2026 08
- 3 Russell 2000 Stocks We Approach with Caution - StockStory Mon, 09 Mar 2026 07
- Life Sciences Tools & Services Stocks Q4 In Review: 10x Genomics (NASDAQ:TXG) Vs Peers - Yahoo Finance Fri, 06 Mar 2026 22
- 10x Genomics $TXG Shares Bought by JPMorgan Chase & Co. - MarketBeat Fri, 06 Mar 2026 09
- How To Trade (TXG) (TXG:CA) - Stock Traders Daily Sun, 08 Mar 2026 03
- Why 10x Genomics (TXG) Stock Is Nosediving - Yahoo Finance hu, 11 Dec 2025 08
- 10x Genomics (NASDAQ:TXG) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat Mon, 02 Mar 2026 08
- 10x Genomics (TXG) Stock Is Up, What You Need To Know - Yahoo Finance Fri, 02 Jan 2026 08
- Why 10x Genomics (TXG) Stock Is Trading Up Today - Yahoo Finance Fri, 07 Nov 2025 08
- Why 10x Genomics (TXG) Stock Is Trading Up Today - Yahoo Finance ue, 11 Nov 2025 08
- 10x Genomics (TXG) Stock Trades Up, Here Is Why - Yahoo Finance Mon, 22 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2750 | — | — | Stock Gift at price 0.00 per share. | SAXONOV SERGE WILSON | Chief Executive Officer | — | 2026-03-03 00:00:00 | D |
| 1 | 16152 | 367097 | — | Sale at price 22.67 - 23.18 per share. | SAXONOV SERGE WILSON | Chief Executive Officer | — | 2026-03-02 00:00:00 | D |
| 2 | 157895 | — | — | Stock Award(Grant) at price 0.00 per share. | SAXONOV SERGE WILSON | Chief Executive Officer | — | 2026-02-26 00:00:00 | D |
| 3 | 88816 | — | — | Stock Award(Grant) at price 0.00 per share. | HINDSON BENJAMIN J | President | — | 2026-02-26 00:00:00 | D |
| 4 | 106579 | — | — | Stock Award(Grant) at price 0.00 per share. | TAICH ADAM | Chief Financial Officer | — | 2026-02-26 00:00:00 | D |
| 5 | 7579 | 147108 | — | Sale at price 19.41 per share. | TEICHMANN SARAH A. | Director | — | 2026-02-25 00:00:00 | D |
| 6 | 7826 | 145379 | — | Sale at price 18.58 per share. | HINDSON BENJAMIN J | President | — | 2026-02-23 00:00:00 | D |
| 7 | 8968 | 166593 | — | Sale at price 18.58 per share. | TAICH ADAM | Chief Financial Officer | — | 2026-02-23 00:00:00 | D |
| 8 | 9632 | 178928 | — | Sale at price 18.58 per share. | SAXONOV SERGE WILSON | Chief Executive Officer | — | 2026-02-23 00:00:00 | D |
| 9 | 50000 | 60000 | — | Conversion of Exercise of derivative security at price 1.20 per share. | SAXONOV SERGE WILSON | Chief Executive Officer | — | 2026-01-05 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 10.48M | 0.00 | -12.81M | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | -45.99M | -133.99M | -144.13M | -128.49M |
| TotalUnusualItems | 49.90M | 0.00 | -60.98M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 49.90M | 0.00 | -60.98M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -43.54M | -182.63M | -255.10M | -166.00M |
| ReconciledDepreciation | 43.82M | 43.71M | 43.62M | 33.01M |
| ReconciledCostOfRevenue | 198.94M | 196.30M | 209.41M | 120.39M |
| EBITDA | 3.91M | -133.99M | -205.11M | -128.49M |
| EBIT | -39.91M | -177.70M | -248.73M | -161.50M |
| NetInterestIncome | 20.05M | 18.93M | 16.85M | 6.17M |
| InterestExpense | 0.00 | 4.00K | 33.00K | 476.00K |
| InterestIncome | 20.05M | 18.93M | 16.89M | 6.65M |
| NormalizedIncome | -82.97M | -182.63M | -206.92M | -166.00M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -43.54M | -182.63M | -255.10M | -166.00M |
| TotalExpenses | 753.71M | 805.34M | 823.08M | 684.35M |
| TotalOperatingIncomeAsReported | -60.98M | -194.56M | -265.33M | -167.94M |
| DilutedAverageShares | 124.75M | 120.45M | 117.17M | 113.86M |
| BasicAverageShares | 124.75M | 120.45M | 117.17M | 113.86M |
| DilutedEPS | -0.35 | -1.52 | -2.18 | -1.46 |
| BasicEPS | -0.35 | -1.52 | -2.18 | -1.46 |
| DilutedNIAvailtoComStockholders | -43.54M | -182.63M | -255.10M | -166.00M |
| NetIncomeCommonStockholders | -43.54M | -182.63M | -255.10M | -166.00M |
| NetIncome | -43.54M | -182.63M | -255.10M | -166.00M |
| NetIncomeIncludingNoncontrollingInterests | -43.54M | -182.63M | -255.10M | -166.00M |
| NetIncomeContinuousOperations | -43.54M | -182.63M | -255.10M | -166.00M |
| TaxProvision | 3.64M | 4.93M | 6.34M | 4.03M |
| PretaxIncome | -39.91M | -177.70M | -248.76M | -161.97M |
| OtherIncomeExpense | 50.93M | -2.07M | -61.27M | -198.00K |
| OtherNonOperatingIncomeExpenses | 1.03M | -2.07M | -286.00K | -198.00K |
| SpecialIncomeCharges | 49.90M | 0.00 | -60.98M | 0.00 |
| OtherSpecialCharges | -49.90M | 60.98M | ||
| RestructuringAndMergernAcquisition | 0.00 | 0.00 | -660.00K | |
| NetNonOperatingInterestIncomeExpense | 20.05M | 18.93M | 16.85M | 6.17M |
| InterestExpenseNonOperating | 0.00 | 4.00K | 33.00K | 476.00K |
| InterestIncomeNonOperating | 20.05M | 18.93M | 16.89M | 6.65M |
| OperatingIncome | -110.89M | -194.56M | -204.35M | -167.94M |
| OperatingExpense | 554.77M | 609.04M | 613.66M | 563.97M |
| ResearchAndDevelopment | 238.63M | 264.70M | 270.33M | 265.67M |
| SellingGeneralAndAdministration | 316.13M | 344.34M | 343.33M | 298.30M |
| GrossProfit | 443.88M | 414.48M | 409.31M | 396.02M |
| CostOfRevenue | 198.94M | 196.30M | 209.41M | 120.39M |
| TotalRevenue | 642.82M | 610.78M | 618.73M | 516.41M |
| OperatingRevenue | 642.82M | 610.78M | 618.73M | 516.41M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 127.69M | 122.29M | 119.10M | 115.20M |
| ShareIssued | 127.69M | 122.29M | 119.10M | 115.20M |
| TotalDebt | 84.36M | 82.61M | 95.37M | 95.18M |
| TangibleBookValue | 729.49M | 689.95M | 719.92M | 778.37M |
| InvestedCapital | 796.33M | 710.13M | 741.04M | 805.74M |
| WorkingCapital | 531.00M | 466.75M | 468.86M | 504.08M |
| NetTangibleAssets | 729.49M | 689.95M | 719.92M | 778.37M |
| CapitalLeaseObligations | 84.36M | 82.61M | 95.37M | 95.18M |
| CommonStockEquity | 796.33M | 710.13M | 741.04M | 805.74M |
| TotalCapitalization | 796.33M | 710.13M | 741.04M | 805.74M |
| TotalEquityGrossMinorityInterest | 796.33M | 710.13M | 741.04M | 805.74M |
| StockholdersEquity | 796.33M | 710.13M | 741.04M | 805.74M |
| GainsLossesNotAffectingRetainedEarnings | 225.00K | -493.00K | -429.00K | -4.33M |
| OtherEquityAdjustments | 225.00K | -493.00K | -429.00K | -4.33M |
| RetainedEarnings | -1.51B | -1.47B | -1.28B | -1.03B |
| AdditionalPaidInCapital | 2.31B | 2.18B | 2.03B | 1.84B |
| CapitalStock | 2.00K | 2.00K | 2.00K | 2.00K |
| CommonStock | 2.00K | 2.00K | 2.00K | 2.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 245.04M | 208.50M | 224.10M | 223.24M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 91.58M | 90.87M | 96.94M | 92.28M |
| OtherNonCurrentLiabilities | 7.71M | 5.03M | 4.28M | 2.98M |
| NonCurrentAccruedExpenses | 0.00 | 5.81M | ||
| NonCurrentDeferredLiabilities | 10.50M | 12.51M | 8.81M | 3.17M |
| NonCurrentDeferredRevenue | 10.50M | 12.51M | 8.81M | 3.17M |
| LongTermDebtAndCapitalLeaseObligation | 73.38M | 73.33M | 83.85M | 86.14M |
| LongTermCapitalLeaseObligation | 73.38M | 73.33M | 83.85M | 86.14M |
| CurrentLiabilities | 153.45M | 117.63M | 127.16M | 130.96M |
| OtherCurrentLiabilities | 41.06M | 14.13M | 12.53M | 9.73M |
| CurrentDeferredLiabilities | 23.90M | 20.66M | 13.15M | 7.87M |
| CurrentDeferredRevenue | 23.90M | 20.66M | 13.15M | 7.87M |
| CurrentDebtAndCapitalLeaseObligation | 10.98M | 9.29M | 11.52M | 9.04M |
| CurrentCapitalLeaseObligation | 10.98M | 9.29M | 11.52M | 9.04M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 32.20M | 24.71M | 21.43M | 20.01M |
| PayablesAndAccruedExpenses | 45.30M | 48.86M | 68.53M | 84.31M |
| CurrentAccruedExpenses | 19.81M | 28.01M | 47.74M | 58.63M |
| Payables | 25.49M | 20.85M | 20.79M | 25.68M |
| OtherPayable | 5.54M | 3.00M | ||
| TotalTaxPayable | 7.22M | 4.94M | 5.05M | 4.08M |
| AccountsPayable | 12.73M | 12.91M | 15.74M | 21.60M |
| TotalAssets | 1.04B | 918.64M | 965.14M | 1.03B |
| TotalNonCurrentAssets | 356.91M | 334.25M | 369.12M | 393.94M |
| OtherNonCurrentAssets | 2.91M | 4.13M | 3.06M | 7.37M |
| GoodwillAndOtherIntangibleAssets | 66.84M | 20.18M | 21.13M | 27.37M |
| OtherIntangibleAssets | 62.33M | 15.67M | 16.62M | 22.86M |
| Goodwill | 4.51M | 4.51M | 4.51M | 4.51M |
| NetPPE | 287.16M | 309.94M | 344.93M | 359.21M |
| AccumulatedDepreciation | -153.46M | -122.97M | -103.49M | -68.83M |
| GrossPPE | 440.62M | 432.90M | 448.42M | 428.04M |
| Leases | 89.72M | 89.57M | 96.41M | 91.52M |
| ConstructionInProgress | 2.93M | 5.15M | 7.25M | 153.00M |
| OtherProperties | 60.45M | 57.29M | 65.36M | 69.88M |
| MachineryFurnitureEquipment | 103.26M | 97.04M | 96.60M | 76.86M |
| BuildingsAndImprovements | 147.49M | 147.09M | 146.04M | 0.00 |
| LandAndImprovements | 36.77M | 36.77M | 36.77M | 36.78M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 684.45M | 584.39M | 596.02M | 635.03M |
| OtherCurrentAssets | 22.21M | 19.41M | 18.79M | 16.58M |
| RestrictedCash | 0.00 | 2.63M | 1.03M | |
| PrepaidAssets | 13.90M | |||
| Inventory | 56.34M | 83.11M | 73.71M | 81.63M |
| FinishedGoods | 23.18M | 16.74M | 17.25M | 22.48M |
| WorkInProcess | 17.14M | 27.44M | 21.98M | 24.65M |
| RawMaterials | 16.02M | 38.93M | 34.48M | 34.50M |
| Receivables | 82.49M | 88.47M | 114.83M | 104.21M |
| OtherReceivables | 35.48M | 606.00K | ||
| AccountsReceivable | 47.01M | 87.86M | 114.83M | 104.21M |
| AllowanceForDoubtfulAccountsReceivable | -100.00K | -100.00K | 0.00 | |
| GrossAccountsReceivable | 114.93M | 104.31M | 85.25M | |
| CashCashEquivalentsAndShortTermInvestments | 523.41M | 393.40M | 388.69M | 429.98M |
| OtherShortTermInvestments | 49.44M | 49.34M | 29.41M | 210.24M |
| CashAndCashEquivalents | 473.97M | 344.07M | 359.28M | 219.75M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 130.12M | -6.73M | -64.72M | -165.27M |
| RepaymentOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 0.00 | 0.00 | ||
| CapitalExpenditure | -5.93M | -13.39M | -49.52M | -131.66M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 436.00K | 841.00K |
| IncomeTaxPaidSupplementalData | 2.39M | 5.64M | 4.93M | 3.92M |
| EndCashPosition | 473.97M | 344.07M | 359.28M | 227.35M |
| BeginningCashPosition | 344.07M | 359.28M | 227.35M | 596.07M |
| EffectOfExchangeRateChanges | 484.00K | -164.00K | -33.00K | -44.00K |
| ChangesInCash | 129.41M | -15.05M | 131.96M | -368.68M |
| FinancingCashFlow | 6.80M | 10.91M | 13.67M | 15.82M |
| CashFlowFromContinuingFinancingActivities | 6.80M | 10.91M | 13.67M | 15.82M |
| NetOtherFinancingCharges | -5.81M | -5.41M | -5.03M | |
| ProceedsFromStockOptionExercised | 6.80M | 10.91M | 19.48M | 21.23M |
| NetCommonStockIssuance | 0.00 | 0.00 | ||
| CommonStockIssuance | 0.00 | 0.00 | ||
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | 0.00 | ||
| LongTermDebtPayments | 0.00 | 0.00 | ||
| InvestingCashFlow | -13.44M | -32.63M | 133.49M | -350.89M |
| CashFlowFromContinuingInvestingActivities | -13.44M | -32.63M | 133.49M | -350.89M |
| NetOtherInvestingChanges | -9.27M | |||
| NetInvestmentPurchaseAndSale | 1.76M | -19.24M | 183.02M | -215.23M |
| SaleOfInvestment | 125.20M | 29.64M | 183.02M | 67.64M |
| PurchaseOfInvestment | -123.44M | -48.88M | 0.00 | -282.87M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -4.00M | -5.45M |
| PurchaseOfBusiness | 0.00 | 0.00 | -4.00M | -5.45M |
| NetIntangiblesPurchaseAndSale | 0.00 | -1.00M | -923.00K | 0.00 |
| PurchaseOfIntangibles | 0.00 | -1.00M | -923.00K | 0.00 |
| NetPPEPurchaseAndSale | -5.93M | -12.39M | -48.60M | -131.66M |
| PurchaseOfPPE | -5.93M | -12.39M | -48.60M | -131.66M |
| OperatingCashFlow | 136.05M | 6.66M | -15.20M | -33.61M |
| CashFlowFromContinuingOperatingActivities | 136.05M | 6.66M | -15.20M | -33.61M |
| ChangeInWorkingCapital | 24.94M | 1.25M | 17.34M | -39.42M |
| ChangeInOtherWorkingCapital | 8.39M | 14.86M | 8.29M | 4.46M |
| ChangeInOtherCurrentLiabilities | -8.91M | -11.71M | -7.39M | -9.37M |
| ChangeInOtherCurrentAssets | 689.00K | -1.08M | -678.00K | 925.00K |
| ChangeInPayablesAndAccruedExpense | -7.28M | -16.09M | 22.28M | 9.19M |
| ChangeInAccruedExpense | -5.15M | -12.74M | 28.30M | 3.34M |
| ChangeInPayable | -2.13M | -3.35M | -6.02M | 5.86M |
| ChangeInAccountPayable | -2.13M | -3.35M | -6.02M | 5.86M |
| ChangeInPrepaidAssets | -2.34M | -1.90M | -2.43M | -4.50M |
| ChangeInInventory | 27.95M | -9.78M | 7.87M | -21.19M |
| ChangeInReceivables | 6.44M | 26.95M | -10.61M | -18.95M |
| ChangesInAccountReceivables | 41.31M | 26.95M | -10.61M | -18.95M |
| OtherNonCashItems | -346.00K | 523.00K | 427.00K | 1.96M |
| StockBasedCompensation | 109.12M | 140.75M | 166.95M | 136.85M |
| AssetImpairmentCharge | 2.07M | 3.05M | 9.85M | 0.00 |
| AmortizationOfSecurities | 427.00K | 871.00K | 0.00 | |
| DepreciationAmortizationDepletion | 43.82M | 43.71M | 43.62M | 33.01M |
| DepreciationAndAmortization | 43.82M | 43.71M | 43.62M | 33.01M |
| Depreciation | 43.82M | 43.71M | 43.62M | 33.01M |
| OperatingGainsLosses | 3.00K | 1.72M | 1.09M | 79.00K |
| GainLossOnInvestmentSecurities | 3.00K | 1.72M | ||
| GainLossOnSaleOfPPE | 1.09M | 79.00K | ||
| NetIncomeFromContinuingOperations | -43.54M | -182.63M | -255.10M | -166.00M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TXG
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|